Forbes R B, Colville S, Cran G W, Swingler R J
Department of Neurology, Ninewells Hospital and Medical School, Dundee, Scotland, UK.
J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1753-5. doi: 10.1136/jnnp.2003.024364.
To describe survival of 1226 Scottish adults with amyotrophic lateral sclerosis/motor neurone disease (ALS/MND).
Ten year, prospective, population based disease register. Cox time dependent proportional hazards modelling for multivariate survival analyses.
Median survival from onset was 25 months (interquartile range 16-34 months). In multivariate models we found an increased hazard with more recently diagnosed cases-that is, there was an unexpected decline in survival over the 10 year period (hazard ratio (HR) 1.06 (95% CI 1.04 to 1.09). Positive effects on survival were demonstrated for longer time from onset to diagnosis (HR 0.38 (95% CI 0.33 to 0.42), assessment by a neurological specialist (HR 0.56 (95% CI 0.40 to 0.77), and treatment with riluzole (HR 0.24 (95% CI 0.14 to 0.42). Poor prognosis was associated with bulbar onset (HR 1.25 (95% CI 1.09 to 1.46) and a mixed lower and upper motor neurone syndrome (HR 1.23 (95% CI 1.01-1.49) and increasing age.
We found an unexpected decline in survival over the 10 year period, despite controlling for potential confounding variables. We would be cautious about over-interpreting these observations and suggest that further research is required to confirm or refute these findings.
描述1226名患有肌萎缩侧索硬化症/运动神经元病(ALS/MND)的苏格兰成年人的生存率。
基于人群的前瞻性疾病登记,为期十年。采用Cox时间依赖性比例风险模型进行多变量生存分析。
从发病起的中位生存期为25个月(四分位间距为16 - 34个月)。在多变量模型中,我们发现近期确诊的病例风险增加,即在这10年期间生存率意外下降(风险比(HR)为1.06(95%置信区间为1.04至1.09)。从发病到诊断的时间更长对生存有积极影响(HR为0.38(95%置信区间为0.33至0.42),由神经科专家进行评估(HR为0.56(95%置信区间为0.40至0.77),以及使用利鲁唑治疗(HR为0.24(95%置信区间为0.14至0.42)。预后不良与延髓发病(HR为1.25(95%置信区间为1.09至1.46)、上下运动神经元混合综合征(HR为1.23(95%置信区间为1.01 - 1.49)以及年龄增加有关。
尽管控制了潜在的混杂变量,但我们发现这10年期间生存率意外下降。我们对过度解读这些观察结果持谨慎态度,并建议需要进一步研究来证实或反驳这些发现。